CClinicalTrials.gg
CompletedNCT03411291Updated Feb 19, 2018

Statins in Cerebral Blood Flow and Neuronal Activity--A Pilot Study

An observational study in Alzheimer's Disease, sponsored by Cedars-Sinai Medical Center. Completed at 1 site in United States. Open to participants aged 45 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-02-19.

Sponsored by Cedars-Sinai Medical Center · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
18
Ages
45 Years to 65 Years
Sex
All
01

Study summary

Specific Aim: Demonstrate that statins have an effect on cerebral blood flow and neuronal activity

Read the detailed description

A number of recent of recent studies suggests that statins, typically used to lower blood cholesterol have an effect on the brain. Patients treated with statins may have increased blood flow in the brain resulting in increased activity of the brain's neurons. The neuronal system is linked to memory. Brain magnetic resonance imaging (MRI) with magnetic resonance spectroscopy (MRS) and magnetic resonance perfusion (MRP) will be used to assess changes in neuronal activity in patients receiving statins vs. patients not receiving statins.

This is a single-site non-randomized pilot study. The study will include twenty (20), healthy consenting patients between the ages of 45 and 65 who are candidates for statin therapy as determined by their cardiologist(s). Two imaging visits will be required, one magnetic resonance imaging with Magnetic Resonance Spectroscopy and Magnetic Resonance Perfusion at baseline and one magnetic resonance imaging with magnetic resonance Spectroscopy and Magnetic Resonance Perfusion three months later as described.

Patients will have selected their course of clinical treatment prior to recruitment. Ten patients will have elected to start statin therapy with Lipitor and ten patients will have elected to initially lower their cholesterol levels with diet, independent of their participation in the study.

Participants on the "statin arm" will receive a dose of 20 mg per day of Lipitor and will receive a baseline brain Magnetic Resonance Imaging with Magnetic Resonance Spectroscopy and Magnetic Resonance Perfusion prior to receiving Lipitor and follow-up brain Magnetic Resonance Imaging with Magnetic Resonance Spectroscopy and Magnetic Resonance Perfusion three months after beginning Lipitor.

Participants on the "diet arm" will receive a baseline brain magnetic resonance imaging with Magnetic Resonance Spectroscopy and Magnetic Resonance Perfusion at the beginning of the study and follow-up brain magnetic resonance imaging with magnetic resonance spectroscopy and magnetic resonance perfusion three months later.

02

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • Alzheimer's, magnetic resonance imaging
03

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

20 patients male and female

Inclusion criteria

  1. Otherwise healthy adults, male or female
  2. Age 45-65,
  3. Prior to treatment with any statin at a moderate or high dose -

Exclusion criteria

Exclusion Criteria:

  1. Previous cerebral vascular accident,
  2. Traumatic brain injury,
  3. Subarachnoid hemorrhage,
  4. Vascular dementia,
  5. Alzheimer's Disease A
  6. Any other known vascular pathologies of the brain.
  7. Patients taking and/or receiving other known cerebrovascular enhancing medication/herbs and/or treatment (examples: tPA, gingko, triple H therapy, stenting procedures, etc.)
  8. Previous neurosurgery or intracranial procedures.
  9. Contraindication to MRI (pacemaker, neurostimulator, other surgical implants or metals which would contraindicate MRI).
04

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
18 participants (actual)
Patient registry
No

Groups and cohorts

  • Diet: MRI/MR Spectroscopy/MR Perfusion

    Healthy candidates for statin therapy to lower cholesterol pre-electing to lower cholesterol by diet for three months. Candidates in this arm have pre-elected to lower cholesterol by diet as described under the care of their treating physicians. Candidates will have 1 (one) brain MRI / MR spectroscopy/MR resonance perfusion scan at baseline and 1 (one) brain MRI / MR spectroscopy/MR resonance perfusion scan at 3 (three) months.

  • Statin: MRI/MR Spectroscopy/MR Perfusion

    Healthy candidates for statin therapy pre-electing to lower their cholesterol using atorvastatin (Lipitor) 20 mg per day as prescribed by their treating physician per standard of care. There are no research-related interventions for this group. Candidates will have 1 (one) brain MRI / MR spectroscopy/MR resonance perfusion scan at baseline and 1 brain MRI / MR spectroscopy/MR resonance perfusion scan at 3 months.

    Device: MRI, MR Spectroscopy, MR Perfusion

Interventions

  • DeviceMRI, MR Spectroscopy, MR Perfusion

    One brain MRI/MR Spectroscopy/MR Perfusion at baseline and one brain MR/MR Spectroscopy/MR Perfusion at 3 months.

05

What researchers measure

Primary outcomes

  1. MRI Spectroscopy

    Changes in metabolite concentration in areas of the brain linked to memory measured by MR spectroscopy with quantitative post processing

    Time frame: 3 months

  2. MRI Perfusion

    Changes in perfusion in areas of the brain linked to memory measured by DCS perfusion imaging

    Time frame: 3 months

06

Study locations

1 site
  • Cedars-Sinai Medical Center, S. Mark Taper Foundation Imaging Center
    Los Angeles, California 90048, United States
07

References and documents

08

Registry details

Key details

Study ID
NCT03411291
Lead sponsor
Cedars-Sinai Medical Center
Responsible party
Franklin G. Moser, M.D. (Director, Neuro-Interventional Imaging; Vice-Chair, Radiology Research, Cedars-Sinai Medical Center) — Principal investigator
First posted
Jan 26, 2018
Start date
Apr 2007
Primary completion
Sep 2010
Completion
Sep 2010
Last update
Feb 19, 2018

Study contacts

Franklin G. Moser, M.D.
principal investigator · Cedars-Sinai Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion